Blood coagulation factor V plays a critical role in the regulation of hemostasis. Regulation of the clotting process is achieved, in part, by the selective inactivation of factor Va with activated protein C. This application is designed to elucidate in greater detail the events which control factor Va activity. Factor V inactivation by activated protein C requires another vitamin K-dependent factor, protein S. Protein S circulates in plasma both free and bound to a regulatory protein of the complement system C4BP. Plasma experiments indicate that the C4BP-protein S complex cannot function in concert with activated protein C to elicit anticoagulant activity. This application seeks to determine whether the C4BP-protein S complex still binds activated protein C, whether the complex is an inhibitor of protein S-activated protein C interaction on liposomes, the platelet surface and/or the endothelial cell surface and whether C4b influences any of these interactions. Preliminary studies indicate that factor Va, but not factor V, is required to support both protein S and activated protein C binding to the platelet surface. More detailed studies will be undertaken to determine which of the factor V derived peptides are required to support activated protein C and protein S binding to either the platelet or endothelial cell surface, or whether, in the case of the endothelial cell, antibodies to factor V/Va block binding. The possibility that factor Va induces formation of a binding site for the protein S-C4BP complex on the surface of platelets, endothelial cells, monocytes and/or lymphocytes will also be examined. These studies may provide an important biochemical link between complement activation and the coagulation system and explain the hypercoagulable states recently observed in several patients. Recent studies provide further evidence that factor Va interaction with prothrombin is an important part of expression of factor Va activity. Studies on the interaction of factor Va with prothrombin will be completed by employing sedimentation equilibrium analysis and by re-examining the influence of prothrombin on factor Va interaction with cell surfaces.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL029807-05
Application #
3340865
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1982-06-01
Project End
1990-12-31
Budget Start
1986-01-01
Budget End
1986-12-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Cooper, Scott T; Rezaie, Alireza R; Esmon, Charles T et al. (2002) Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. Thromb Res 107:67-73
Yegneswaran, S; Smirnov, M D; Safa, O et al. (1999) Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 274:5462-8
Yegneswaran, S; Wood, G M; Esmon, C T et al. (1997) Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem 272:25013-21
Esmon, C T (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9:946-55
Ye, J; Esmon, C T (1995) Factor Xa-factor Va complex assembles in two dimensions with unexpectedly high affinity: an experimental and theoretical approach. Biochemistry 34:6448-53
Rezaie, A R; Esmon, C T (1995) Contribution of residue 192 in factor Xa to enzyme specificity and function. J Biol Chem 270:16176-81
Rezaie, A R; Esmon, C T (1995) Tryptophans 231 and 234 in protein C report the Ca(2+)-dependent conformational change required for activation by the thrombin-thrombomodulin complex. Biochemistry 34:12221-6
Esmon, C T (1995) Inflammation and thrombosis: the impact of inflammation on the protein C anticoagulant pathway. Haematologica 80:49-56
Esmon, C T; Fukudome, K (1995) Cellular regulation of the protein C pathway. Semin Cell Biol 6:259-68
Rezaie, A R; Cooper, S T; Church, F C et al. (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 270:25336-9

Showing the most recent 10 out of 71 publications